COBISS Kooperativni online bibliografski sistem in servisi COBISS
Bhaswati Mukherjee
Osebna bibliografija za obdobje 2022-2023
2022
1.
BATTELINO, Tadej, DANNE, Thomas, EDELMAN, Scymour, CHOUDHARY, P., RENARD, Eric, WESTERBACKA,
Jukka, MUKHERJEE, Bhaswati, PICARD, Philippe, PILORGET, Valerie, BERGENSTAL, Richard.
Comparison of second-generation basal insulin analogues glargine 300 u/ml and degludec
100 u/ml using continuous glucose monitoring in people with T1D : inrange randomised
controlled trial. Diabetes technology & therapeutics. 2022, vol. 24, iss. s2, str. a-4. ISSN 1557-8593. https://www.liebertpub.com/doi/10.1089/dia.2022.2527.abstracts, DOI: 10.1089/dia.2022.2527.abstracts. [COBISS.SI-ID 150672643]
2023
2.
BATTELINO, Tadej (avtor, korespondenčni avtor), DANNE, Thomas, EDELMAN, Steve, CHOUDHARY,
Pratik, RENARD, Eric, WESTERBACKA, Jukka, MUKHERJEE, Bhaswati, PILORGET, Valerie,
COUDERT, Mathieu, BERGENSTAL, Richard. Continuous glucose monitoring-based time-in-range
usinginsulin glargine 300 units/ml versus insulin degludec100 units/ml in type 1 diabetes
: the head-to-head randomizedcontrolled InRange trial. Diabetes, obesity & metabolism. 2023, vol. 25, iss. 2, [article no.] 14898, 545-555 str., ilustr. ISSN 1463-1326.
https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14898, Repozitorij Univerze v Ljubljani – RUL, DiRROS - Digitalni repozitorij raziskovalnih organizacij Slovenije, DOI: 10.1111/dom.14898. [COBISS.SI-ID 143145987]
projekt: P3-0343; financer: Slovenian Research Agency
projekt: DK108611; financer: National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Health)
projekt: Sofinancerji: Novo Nordisk, Sanofi, Eli Lilly, Boehringer Ingelheim, Indigo and Medtronic, AstraZeneca, Pfizer, Dxcom, Abbott and Roche, Abbott Diabetes Care, Sandoz, Novartis and Zealand Pharma
projekt: P3-0343; financer: Slovenian Research Agency
projekt: DK108611; financer: National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Health)
projekt: Sofinancerji: Novo Nordisk, Sanofi, Eli Lilly, Boehringer Ingelheim, Indigo and Medtronic, AstraZeneca, Pfizer, Dxcom, Abbott and Roche, Abbott Diabetes Care, Sandoz, Novartis and Zealand Pharma